Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?

24 Sep 2001

• By The Pink Sheet

Bristol-Myers Squibb's $2 bil. investment in ImClone's anti-cancer monoclonal antibody C225 (cetuximab) represents a $500 mil. premium to the company's estimate of the peak annual sales potential for the agent.

Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?

More from Archive

More from Pink Sheet